Pro Nephro AKI (NGAL) is now FDA-Cleared READ MORE

Announcements

Investor News

BioPorto A/S

BioPorto A/S appoints new interim Chairman of the Board

Wed, 29 Jan 2025 17:16 GMT

BioPorto A/S

BioPorto A/S vælger ny midlertidig bestyrelsesformand

Wed, 29 Jan 2025 17:16 GMT

BioPorto A/S

BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals

Thu, 23 Jan 2025 12:23 GMT

BioPorto A/S

BioPorto annoncerer offentliggørelse af NGAL-referenceintervaller i urin hos raske voksne og pædiatriske individer

Thu, 23 Jan 2025 12:23 GMT

BioPorto A/S

Preliminary Financial Figures for the 2024 Fiscal Year

Mon, 06 Jan 2025 17:16 GMT

BioPorto A/S

Foreløbige finansielle tal for regnskabsåret 2024

Mon, 06 Jan 2025 17:16 GMT

BioPorto A/S

BioPorto commences process to appoint new Chair of the Board of Directors

Mon, 16 Dec 2024 17:53 GMT

BioPorto A/S

BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024

Thu, 14 Nov 2024 07:50 GMT

BioPorto A/S

BioPorto offentliggør delårsresultater og opdatering for tredje kvartal og ni måneder af regnskabsåret 2024

Thu, 14 Nov 2024 07:50 GMT

BioPorto A/S

BioPorto A/S to Host Third Quarter 2024 Earnings Webcast

Tue, 12 Nov 2024 08:57 GMT

BioPorto A/S

BioPorto A/S inviterer til webcast

Tue, 12 Nov 2024 08:57 GMT

BioPorto A/S

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

Fri, 08 Nov 2024 16:03 GMT

BioPorto A/S

Grant of Warrants

Mon, 04 Nov 2024 17:44 GMT

BioPorto A/S

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital

Tue, 29 Oct 2024 07:56 GMT

BioPorto A/S

Første patient indrulleret - BioPorto har påbegyndt indrullering til det amerikanske studie vedrørende ProNephro AKI (NGAL)™ til voksen brug ved Massachusetts General Hospital

Tue, 29 Oct 2024 07:56 GMT

BioPorto A/S

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

Mon, 28 Oct 2024 15:26 GMT

BioPorto A/S

BioPorto indgår globalt distributionspartnerskab med Beckman Coulter om NGAL Tests til akut nyreskade

Mon, 28 Oct 2024 15:26 GMT

BioPorto A/S

BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference

Wed, 23 Oct 2024 15:15 GMT

BioPorto A/S

BioPorto præsenterer den FDA-godkendte ProNephro AKI (NGAL) test på ASN Kidney Week 2024 Conference

Wed, 23 Oct 2024 15:15 GMT

BioPorto A/S

BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL

Tue, 22 Oct 2024 06:04 GMT

Follow this link to view all historical announcements.